AR059249A1 - Compuesto amina trisustituido - Google Patents
Compuesto amina trisustituidoInfo
- Publication number
- AR059249A1 AR059249A1 ARP070100395A ARP070100395A AR059249A1 AR 059249 A1 AR059249 A1 AR 059249A1 AR P070100395 A ARP070100395 A AR P070100395A AR P070100395 A ARP070100395 A AR P070100395A AR 059249 A1 AR059249 A1 AR 059249A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- group
- substituted
- optionally
- homocyclic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Posee una actividad inhibitoria contra la proteína de transferencia de colesteril éster (CETP), siendo por eso util para la profilaxis y/o tratamiento de enfermedades relacionadas con arteriosclerosis, hiperlipidemia o dislipidemia, y lo similar. Reivindicacion 1: Un compuesto caracterizado porque posee la formula general (1), A es (i) un grupo seleccionado de un grupo alquinilo opcionalmente sustituido, un átomo halogeno, un grupo oxo, un grupo hidroxilo, un grupo ciano, nitro, carboxilo, sulfo, alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alcoxilo opcionalmente sustituido, cicloalcoxilo opcionalmente sustituido, alcoxicarbonilo opcionalmente sustituido, carbamoilo opcionalmente sustituido, carbamimidoilo opcionalmente sustituido, alquilsulfanilo opcionalmente sustituido, alquilsulfinilo opcionalmente sustituido, alquilsulfonilo opcionalmente sustituido, amino opcionalmente sustituido, sulfamoilo opcionalmente sustituido, alcanoilo opcionalmente sustituido, un grupo homocíclico opcionalmente sustituido, un grupo oxilo sustituido por grupo homocíclico opcionalmente sustituido, un grupo carbonilo sustituido por el grupo homocíclico opcionalmente sustituido, un grupo heterocíclico opcionalmente sustituido, un grupo oxilo sustituido por grupo heterocíclico opcionalmente sustituido, y un grupo carbonilo sustituido por el grupo heterocíclico opcionalmente sustituido; (ji) un grupo homocíclico opcionalmente sustituido por 1 a 5 sustituyentes seleccionados independientemente de los grupos como los definidos precedentemente en (i); o (iii) un grupo heterocíclico opcionalmente sustituido por 1 a 5 sustituyentes seleccionados independientemente de grupos como los definidos precedentemente en (i); B es un grupo fenilo opcionalmente sustituido por 1 a 4 sustituyentes seleccionados independientemente de los grupos siguientes: un grupo alquinilo opcionalmente sustituido un átomo halogeno, un grupo hidroxilo, ciano, nitro, carboxilo, sulfo, alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alcoxilo opcionalmente sustituido, cicloalcoxilo opcionalmente sustituido, alcoxicarbonilo opcionalmente sustituido, carbamoilo opcionalmente sustituido, carbamimidoilo opcionalmente sustituido, alquilsulfanilo opcionalmente sustituido, alquilsulfinilo opcionalmente sustituido, alquilsulfonilo opcionalmente sustituido, un grupo amino opcionalmente sustituido, un sulfamoilo opcionalmente sustituido; un alcanoilo opcionalmente sustituido, un grupo homocíclico opcionalmente sustituido, un grupo oxilo sustituido por el grupo homocíclico opcionalmente sustituido, un grupo carbonilo sustituido por grupo homocíclico opcionalmente sustituido, un grupo heterocíclico opcionalmente sustituido, un grupo oxilo sustituido por el grupo heterocíclico opcionalmente sustituido, un grupo carbonilo sustituido por grupo heterocíclico opcionalmente sustituido, y un grupo alquileno; en donde dicho grupo alquileno puede tener 1 a 3 heteroátomos seleccionados independientemente de átomos de oxígeno, azufre y nitrogeno y además opcionalmente puede tener sustituyente(s); R1 es un átomo de hidrogeno o un grupo alquilo opcionalmente sustituido; en donde el grupo alquilo además puede ser opcionalmente sustituido por sustituyente(s) seleccionado(s) de un grupo homocíclico opcionalmente sustituido y un grupo heterocíclico opcionalmente sustituido; R2 es un grupo seleccionado de un grupo alquinilo opcionalmente sustituido, un átomo halogeno, un grupo oxo, hidroxilo, ciano, nitro, carboxilo, sulfo, un grupo alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alcoxilo opcionalmente sustituido, cicloalcoxilo opcionalmente; alcoxicarbonilo opcionalmente sustituido, carbamoilo opcionalmente sustituido, carbamimidoilo opcionalmente sustituido, alquilsulfanilo opcionalmente sustituido, alquilsulfinilo opcionalmente sustituido, alquilsulfonilo opcionalmente sustituido, amino opcionalmente sustituido, sulfamoilo opcionalmente sustituido, alcanoilo opcionalmente sustituido, un grupo homocíclico opcionalmente sustituido, un grupo oxo sustituido por el grupo homocíclico opcionalmente sustituido, un grupo carbonilo sustituido por el grupo homocíclico opcionalmente sustituido, un grupo heterocíclico opcionalmente sustituido, un grupo oxo sustituido por el grupo heterocíclico opcionalmente sustituido, y un grupo carbonilo sustituido por el grupo heterocíclico opcionalmente sustituido, o un derivado farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006023572 | 2006-01-31 | ||
JP2006322853 | 2006-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059249A1 true AR059249A1 (es) | 2008-03-19 |
Family
ID=38042898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070100395A AR059249A1 (es) | 2006-01-31 | 2007-01-30 | Compuesto amina trisustituido |
Country Status (18)
Country | Link |
---|---|
US (2) | US7906517B2 (es) |
EP (1) | EP1979331B1 (es) |
JP (1) | JP4943443B2 (es) |
KR (2) | KR20110132452A (es) |
CN (2) | CN101374817B (es) |
AR (1) | AR059249A1 (es) |
AT (1) | ATE548356T1 (es) |
AU (1) | AU2007210446B2 (es) |
BR (1) | BRPI0706790A2 (es) |
CA (1) | CA2634676C (es) |
DK (1) | DK1979331T3 (es) |
ES (1) | ES2381042T3 (es) |
PL (1) | PL1979331T3 (es) |
PT (1) | PT1979331E (es) |
RU (1) | RU2412937C2 (es) |
TW (1) | TWI352086B (es) |
UY (1) | UY30117A1 (es) |
WO (1) | WO2007088996A1 (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006138304A2 (en) * | 2005-06-14 | 2006-12-28 | Taigen Biotechnology | Pyrimidine compounds |
JP2009508835A (ja) | 2005-09-16 | 2009-03-05 | アロー セラピューティクス リミテッド | ビフェニル誘導体及びc型肝炎の治療におけるその使用 |
UY30117A1 (es) * | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
PE20071025A1 (es) * | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
US7919506B2 (en) * | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
ES2533910T3 (es) * | 2007-04-13 | 2015-04-15 | Kowa Company, Ltd. | Compuesto novedoso de pirimidina que tiene estructura de dibencilamina y medicamento que comprende el compuesto |
JP2010528019A (ja) | 2007-05-22 | 2010-08-19 | アキリオン ファーマシューティカルズ,インコーポレーテッド | ヘテロアリール置換チアゾール |
JP4834699B2 (ja) * | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
KR101235961B1 (ko) | 2008-02-01 | 2013-02-21 | 판미라 파마슈티칼스, 엘엘씨 | 프로스타글란딘 d2 수용체의 n,n-이치환 아미노알킬비페닐 길항제 |
JP2011513242A (ja) | 2008-02-25 | 2011-04-28 | アミラ ファーマシューティカルズ,インク. | プロスタグランジンd2受容体アンタゴニスト |
CN102099036B (zh) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
JP5319457B2 (ja) * | 2008-08-25 | 2013-10-16 | 興和株式会社 | 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬 |
JPWO2010029756A1 (ja) * | 2008-09-12 | 2012-02-02 | 興和株式会社 | 5−[2−(メチルチオ)エトキシ]ピリミジン−2−アミンの製造方法 |
GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
US8841478B2 (en) | 2008-11-28 | 2014-09-23 | Kowa Company, Ltd. | Method for preparing trans-{4-[(alkylamino) methyl]- cyclohexyl}acetic acid ester |
KR20120047273A (ko) | 2009-08-05 | 2012-05-11 | 판미라 파마슈티칼스, 엘엘씨 | Dp2 길항제 및 이의 용도 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
TWI627167B (zh) | 2011-07-08 | 2018-06-21 | 諾華公司 | 用於高三酸甘油酯個體治療動脈粥狀硬化之方法 |
WO2014017569A1 (ja) * | 2012-07-26 | 2014-01-30 | 興和株式会社 | 血中ldlを低下させるための医薬 |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
CN110452216B (zh) | 2014-04-02 | 2022-08-26 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
DK3177612T3 (da) | 2014-08-04 | 2022-05-16 | Nuevolution As | Eventuelt fusionerede heterocyclylsubstituerede derivater af pyrimidin, der er anvendelige til behandling af inflammatoriske, metaboliske, onkologiske og autoimmune sygdomme |
EP3186242B1 (en) | 2014-08-29 | 2021-10-06 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
GB201501302D0 (en) | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
CN106032362B (zh) * | 2015-03-10 | 2018-06-19 | 湖南千金湘江药业股份有限公司 | 安塞曲匹的制备方法 |
GB201517523D0 (en) | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
CN109641842B (zh) | 2016-08-26 | 2021-12-07 | 住友化学株式会社 | 1-苯基-3-氨基甲酰基脲化合物及其用途 |
JP6847962B2 (ja) | 2016-08-26 | 2021-03-24 | 住友化学株式会社 | 1−アセチル−3−フェニルウレア化合物及びその用途 |
CA3035001A1 (en) | 2016-08-26 | 2018-03-01 | Sumitomo Chemical Company, Limited | Phenyl urea compound, and use thereof |
PE20201164A1 (es) | 2017-07-11 | 2020-10-28 | Vertex Pharma | Carboxamidas como moduladores de los canales de sodio |
CN111683976B (zh) | 2018-02-05 | 2022-11-18 | 生物辐射实验室股份有限公司 | 具有阴离子交换-疏水混合模式配体的色谱树脂 |
MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
MX2022012259A (es) | 2020-03-31 | 2022-12-08 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4552960A (en) * | 1983-06-20 | 1985-11-12 | Eli Lilly And Company | Fungicidal amines |
US5536718A (en) * | 1995-01-17 | 1996-07-16 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
TW591026B (en) * | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
US6685617B1 (en) * | 1998-06-23 | 2004-02-03 | Pharmacia & Upjohn Company | Inhibitors of α4β1 mediated cell adhesion |
US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6780883B2 (en) * | 1998-11-05 | 2004-08-24 | Warner-Lambert Company | Amide inhibitors of microsomal triglyceride transfer protein |
DE10201579A1 (de) * | 2001-01-18 | 2002-07-25 | Nippon Catalytic Chem Ind | Vernetzbare Harzzusammensetzung und damit behandeltes Produkt |
CA2460149A1 (en) * | 2001-09-12 | 2003-03-27 | Kaken Pharmaceutical Co., Ltd. | 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same |
JP2003221376A (ja) * | 2001-11-21 | 2003-08-05 | Japan Tobacco Inc | Cetp活性阻害剤 |
WO2003063868A1 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
JP3630676B2 (ja) * | 2002-08-30 | 2005-03-16 | 日本たばこ産業株式会社 | ジベンジルアミン化合物及びその医薬用途 |
ES2277142T3 (es) * | 2002-08-30 | 2007-07-01 | Japan Tobacco Inc. | Compuesto de dibencilamina y su uso medicinal. |
AU2005233160B2 (en) * | 2004-04-13 | 2011-06-02 | Merck Sharp & Dohme Corp. | CETP inhibitors |
PE20061124A1 (es) * | 2004-11-23 | 2006-10-13 | Pfizer Prod Inc | Compuestos y derivados de dibencil amina |
WO2006073973A2 (en) | 2004-12-31 | 2006-07-13 | Reddy Us Therapeutics, Inc. | Novel benzylamine derivatives as cetp inhibitors |
US20100167986A1 (en) | 2005-09-30 | 2010-07-01 | Amjad Ali | Cholesteryl Ester Transfer Protein Inhibitors |
UY30117A1 (es) * | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
-
2007
- 2007-01-29 UY UY30117A patent/UY30117A1/es not_active Application Discontinuation
- 2007-01-30 AT AT07707991T patent/ATE548356T1/de active
- 2007-01-30 KR KR1020117024373A patent/KR20110132452A/ko not_active Application Discontinuation
- 2007-01-30 AU AU2007210446A patent/AU2007210446B2/en not_active Ceased
- 2007-01-30 WO PCT/JP2007/051861 patent/WO2007088996A1/en active Application Filing
- 2007-01-30 CN CN200780003923.0A patent/CN101374817B/zh not_active Expired - Fee Related
- 2007-01-30 RU RU2008135364/04A patent/RU2412937C2/ru not_active IP Right Cessation
- 2007-01-30 ES ES07707991T patent/ES2381042T3/es active Active
- 2007-01-30 KR KR1020087018895A patent/KR101110029B1/ko not_active IP Right Cessation
- 2007-01-30 BR BRPI0706790-9A patent/BRPI0706790A2/pt not_active IP Right Cessation
- 2007-01-30 CN CN201310020236.7A patent/CN103172562B/zh not_active Expired - Fee Related
- 2007-01-30 AR ARP070100395A patent/AR059249A1/es not_active Application Discontinuation
- 2007-01-30 PT PT07707991T patent/PT1979331E/pt unknown
- 2007-01-30 DK DK07707991.1T patent/DK1979331T3/da active
- 2007-01-30 JP JP2008535204A patent/JP4943443B2/ja not_active Expired - Fee Related
- 2007-01-30 EP EP07707991A patent/EP1979331B1/en active Active
- 2007-01-30 CA CA2634676A patent/CA2634676C/en not_active Expired - Fee Related
- 2007-01-30 PL PL07707991T patent/PL1979331T3/pl unknown
- 2007-01-31 TW TW096103470A patent/TWI352086B/zh not_active IP Right Cessation
-
2008
- 2008-07-28 US US12/219,775 patent/US7906517B2/en not_active Expired - Fee Related
-
2010
- 2010-12-20 US US12/973,403 patent/US8076364B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2007210446A8 (en) | 2008-09-11 |
KR20110132452A (ko) | 2011-12-07 |
RU2008135364A (ru) | 2010-03-10 |
US8076364B2 (en) | 2011-12-13 |
ES2381042T3 (es) | 2012-05-22 |
EP1979331A1 (en) | 2008-10-15 |
BRPI0706790A2 (pt) | 2011-04-05 |
CA2634676A1 (en) | 2007-08-09 |
AU2007210446A1 (en) | 2007-08-09 |
KR101110029B1 (ko) | 2012-07-12 |
CA2634676C (en) | 2011-04-26 |
PL1979331T3 (pl) | 2012-10-31 |
TW200800947A (en) | 2008-01-01 |
JP2009524577A (ja) | 2009-07-02 |
CN101374817B (zh) | 2014-07-30 |
ATE548356T1 (de) | 2012-03-15 |
KR20080083047A (ko) | 2008-09-12 |
RU2412937C2 (ru) | 2011-02-27 |
DK1979331T3 (da) | 2012-04-10 |
AU2007210446B2 (en) | 2010-12-23 |
PT1979331E (pt) | 2012-04-03 |
CN103172562A (zh) | 2013-06-26 |
UY30117A1 (es) | 2007-06-29 |
EP1979331B1 (en) | 2012-03-07 |
CN103172562B (zh) | 2015-04-22 |
JP4943443B2 (ja) | 2012-05-30 |
US20090029994A1 (en) | 2009-01-29 |
TWI352086B (en) | 2011-11-11 |
CN101374817A (zh) | 2009-02-25 |
US20110092506A1 (en) | 2011-04-21 |
US7906517B2 (en) | 2011-03-15 |
WO2007088996A1 (en) | 2007-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059249A1 (es) | Compuesto amina trisustituido | |
AR059248A1 (es) | Heterociclos nitrogenados y sus usos como inhibidores de aterosclerosis. composiciones farmaceuticas | |
AR107377A2 (es) | Compuestos derivados de tetrahidroquinolina | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
DE602006007012D1 (de) | Pyridinderivate als dipeptedyl-peptidase-hemmer | |
AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
PE20091653A1 (es) | Derivados sustituidos de pirazol y su uso | |
MX2010000658A (es) | Derivados de pirimidina 934. | |
AR049276A1 (es) | Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen | |
EA201070864A1 (ru) | Новые гетероциклические соединения | |
WO2006123165A3 (en) | Pyrimidine derivatives as hsp90 inhibitors | |
PE20060525A1 (es) | Compuestos heterociclicos como inhibidores de cetp | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
PE20110854A1 (es) | DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1 | |
CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
AR061567A1 (es) | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos | |
PE20081393A1 (es) | Derivados de quinolina como inhibidores de csf-1r | |
DE602005008953D1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
PE20210373A1 (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos | |
ES2496592T3 (es) | Proceso para la preparación de Imatinib y compuestos intermedios del mismo | |
MX2010008637A (es) | Derivado de fenilpirrol novedoso. | |
PE20091243A1 (es) | Compuesto heterociclico fusionado |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |